Effect of Quercetin on Prophylaxis and Treatment of COVID-19

The Possible Effect of Quercetin on Prophylaxis and Treatment of COVID-19

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04377789

Enrollment

447

Registered

2020-05-06

Start date

2020-03-20

Completion date

2020-08-31

Last updated

2021-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Brief summary

Novel Coronavirus is defined to be the cause of COVID-19, recently. It's known that COVID-19 goes with excessive immune reaction of human body in severe cases. The investigators hypothesize that quercetin, as a strong scavenger and anti-inflammatory agent, can be effective on both prophylaxis and treatment of COVID-19 cases. Therefore, the aim of this study to evaluate the possible role of quercetin on prophylaxis and treatment of COVID-19.

Detailed description

Novel Coronavirus is defined to be the cause of COVID-19, recently. It's known that COVID-19 goes with excessive immune reaction of human body in severe cases. Quercetin is reported to be effective on treatment and prophylaxis of other SARS like coronavirus infections, as a strong antioxidant and scavenger flavonoid without any adverse events. Upon this data, the investigators hypothesize that quercetin can be effective on both prophylaxis and treatment of COVID-19 cases. Therefore, the aim of this study to evaluate the possible role of quercetin on prophylaxis and treatment of COVID-19.

Interventions

DIETARY_SUPPLEMENTQuercetin Prophylaxis

a daily dose of quercetin (500mg) will be taken by non-COVID-19 intervention group 1

DIETARY_SUPPLEMENTQuercetin Treatment

a daily dose of quercetin (1000mg) will be taken by proven COVID-19 cases intervention group 2

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* moderate-high risk for COVID-19 * obtained informed consent

Exclusion criteria

* declined to participate * genetic/chromosomal abnormalities * any kind of sensitivity or allergy for quercetin * history of previous hypersensitivity with quercetin

Design outcomes

Primary

Measure	Time frame	Description
Prevalence of COVID-19 calculated using a questionnaire	3 months	Prevalence of COVID-19 in prophylaxis and sham group will be calculated using a questionnaire including hospital records
Standardized Mortality rate	3 months	Mortality rate will be compared between two groups

Secondary

Measure	Time frame	Description
Morbidity rate	3 months	Morbidity rates besides recovery rates from COVID-19 will be documented

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026